- Pentacel(R) vaccine is the first 5-in-1 pediatric combination for immunization against diphtheria, tetanus, pertussis, polio and Haemophilus
influenzae type b (Hib) -
SWIFTWATER, Pa. and LYON, France, June 23 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Pentacel(R), Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine. Pentacel(R) vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b (Hib). Pentacel(R) vaccine is approved for use in infants and children 6 weeks through 4 years of age (prior to fifth birthday).
Pentacel(R) vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.
Pentacel(R) vaccine is approved for administration as a four-dose series at 2, 4, 6 and 15-18 months of age. The first dose may be given as early as 6 weeks of age. According to the current Recommended Childhood Immunization Schedule of the U.S. Centers for Disease Control and Prevention (CDC), up to 23 injections are needed by the time a child reaches 18 months of age with single-entity vaccines. The use of Pentacel(R) vaccine could reduce that number of shots by seven.
"Pentacel(R) vaccine will help simplify the immunization schedule by
reducing the number of injections infants and young children will receive
in their first two years of life," said Wayne Pisano, President and Chief
Executive Officer, sanofi pasteur. Pentacel(R) vaccine has been used in
Canada for a decade and is licensed in seven other countries. "We are
pleased that the U.S. FDA has now take
|SOURCE Sanofi Pasteur|
Copyright©2008 PR Newswire.
All rights reserved